Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsPOC Diagnostics

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2101314

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2101314

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease, Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx ), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2031

PUBLISHED:
PAGES: 548 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The Point of Care Diagnostics market is projected to reach USD 31.46 billion by 2031 from USD 20.63 billion in 2026, growing at a CAGR of 8.8%.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsProduct, Sample, Mode of Purchase, Technology, End User, And Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Continuous technological advancements and the growing demand for rapid, accurate, and decentralized testing are driving growth in the point-of-care diagnostics market. Biochemistry technology accounts for the largest market share due to its widespread use in blood glucose monitoring, blood gas and electrolyte analysis, cholesterol testing, and other routine diagnostic applications across hospitals, clinical laboratories, emergency departments, and physician offices. Its broad clinical utility, cost-effectiveness, and ability to deliver rapid results make it the preferred technology for high-volume point-of-care testing. Meanwhile, molecular diagnostics is projected to grow the fastest, owing to the increasing adoption of rapid PCR-based platforms for infectious disease detection, antimicrobial resistance testing, and outbreak preparedness. Continuous innovations in immunoassays, molecular platforms, microfluidics, multiplex testing, and portable analyzers are improving diagnostic accuracy, reducing turnaround time, and expanding testing beyond traditional laboratories. These advancements are accelerating the adoption of next-generation point-of-care diagnostic technologies across hospitals, ambulatory care facilities, retail clinics, pharmacies, and home healthcare settings, thereby creating sustained global demand for advanced diagnostic solutions.

Point of Care Diagnostics Market - IMG1

Based on product: Infectious disease testing products are projected to register the highest growth during the forecast period. The segment's dominance is driven by the increasing burden of infectious diseases, the growing demand for rapid, accurate near-patient diagnosis, and the need for timely clinical decision-making to support effective treatment and infection control. The growing adoption of point-of-care testing across hospitals, emergency departments, physicians' offices, retail clinics, pharmacies, and home healthcare settings, coupled with expanding government initiatives for infectious disease surveillance and decentralized healthcare delivery, continues to strengthen the market position of infectious disease testing products.

Based on end user: Clinical laboratories account for the largest share of the point-of-care diagnostics market due to their central role in delivering rapid and accurate diagnostic testing for both acute and chronic diseases. These facilities routinely perform point-of-care testing for infectious diseases, diabetes, cardiovascular disorders, coagulation monitoring, and clinical chemistry, supporting timely diagnosis and treatment decisions. Their extensive testing capabilities, skilled laboratory personnel, established quality management systems, and seamless integration with hospital workflows continue to drive demand for point-of-care diagnostic solutions. Furthermore, increasing test volumes, the growing emphasis on faster turnaround times, and the expanding adoption of decentralized testing within laboratory networks reinforce the dominance of clinical laboratories in the global point-of-care diagnostics market.

North America accounts for the largest share of the point-of-care diagnostics market due to its advanced healthcare infrastructure, strong reimbursement framework, and widespread adoption of decentralized diagnostic testing. The region has an extensive network of hospitals, clinical laboratories, physicians' offices, urgent care centers, retail clinics, and pharmacies that routinely use point-of-care diagnostics to rapidly detect and manage infectious diseases, diabetes, cardiovascular disorders, and respiratory conditions. High healthcare expenditure, a strong presence of leading diagnostic manufacturers, and favorable regulatory support have accelerated the adoption of point-of-care testing across the U.S. and Canada. Furthermore, increasing emphasis on early diagnosis, improved patient outcomes, and reducing healthcare costs through near-patient testing continues to reinforce North America's leadership in the global point-of-care diagnostics market.

A breakdown of the primary respondents (supply-side) for the POC diagnostics s market referred to in this report is provided below:

  • By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
  • By Designation: C-level: 55%, Director Level: 27%, and Others: 18%
  • By Region: North America: 43%, Europe: 28%, Asia Pacific: 20%, Latin America: 6%, and Middle East & Africa: 3%

Prominent players in the global point-of-care diagnostics market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), bioMerieux SA (France), Werfen S.A. (Spain), Becton, Dickinson and Company (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), OraSure Technologies, Inc. (US), EKE Diagnostics (China), Trinity Biotech plc (Ireland), Grifols S.A. (Spain), Nova Biomedical Corporation (US), Sekisui Diagnostics, LLC (US), Trividia Health, Inc. (US), Sysmex Corporation (Japan), HemoCue AB (Sweden), and Bio-Rad Laboratories, Inc. (US) among others.

Research Coverage

The report evaluates the POC diagnostics market and estimates the market size and future growth potential of this market based on various segments, including product, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will assist market leaders and new entrants in the POC diagnostics s market with data on the nearest approximations of revenue figures for the overall market and its subsegments. The report will help stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. It also enables stakeholders to understand market dynamics and provides insights into key drivers, restraints, challenges, and growth opportunities influencing the POC diagnostics market.

This report provides insights into the following points:

  • Analysis of key drivers (rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and infectious diseases requiring rapid diagnosis, growing demand for decentralized and near-patient testing to enable faster clinical decision-making, increasing adoption of portable and user-friendly diagnostic devices in hospitals, clinics, and home care settings, technological advancements in microfluidics, biosensors, AI-enabled diagnostics, and smartphone-integrated testing solutions), restraints (high cost of advanced point-of-care diagnostic devices and consumables, stringent regulatory approval and quality compliance requirements, limited accuracy of certain rapid tests compared to centralized laboratory testing, data security and interoperability concerns with connected diagnostic systems), opportunities (expansion of point-of-care testing in emerging markets, increasing demand for home-based diagnostic kits and self-testing solutions, growing adoption of multiplex and molecular point-of-care diagnostics, rising investments in digital health, telemedicine, and AI-powered diagnostic platforms), and challenges (limited healthcare infrastructure and trained personnel in low-resource settings, reimbursement and pricing pressures, supply chain constraints for diagnostic reagents and consumables, standardization and integration of point-of-care diagnostic data with electronic health record systems)
  • Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global POC diagnostics market.
  • Market Development: Thorough knowledge and analysis of the profitable rising markets by product, sample, mode of purchase, technology, end user, and region.
  • Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global POC diagnostics market.
  • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global POC diagnostics market.
Show more
Product Code: MD 2702

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET
  • 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 POC DIAGNOSTICS MARKET OVERVIEW
  • 3.2 POC DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031
  • 3.3 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2026 VS. 2031
  • 3.4 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031
  • 3.5 POC DIAGNOSTICS MARKET, BY SAMPLE, 2026 VS. 2031
  • 3.6 POC DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031
  • 3.7 POC DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Growing incidence of infectious diseases
      • 4.2.1.2 Increasing prevalence of chronic diseases
      • 4.2.1.3 Favorable government initiatives for POC testing
      • 4.2.1.4 Rising number of waived tests
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Pricing pressure on manufacturers
      • 4.2.2.2 Stringent regulatory approval process for product commercialization
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Increasing growth potential in emerging markets
      • 4.2.3.2 Rising inclination toward decentralized healthcare systems
      • 4.2.3.3 Booming healthcare spending worldwide
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Inadequate standardization with centralized lab methods
      • 4.2.4.2 Premium pricing of novel platforms
  • 4.3 UNMET NEEDS AND WHITE SPACES
    • 4.3.1 UNMET NEEDS IN POC DIAGNOSTICS MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
    • 4.5.1 KEY MOVES AND STRATEGIC FOCUS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 INVESTMENT AND FUNDING SCENARIO
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE, BY PRODUCT
      • 5.6.1.1 Average selling price OF glucose monitoring test strips, by key player
    • 5.6.2 AVERAGE SELLING PRICE, BY REGION
      • 5.6.2.1 Average selling price of glucose monitoring test strips, by region
      • 5.6.2.2 Average selling price of infectious disease testing products, by region
      • 5.6.2.3 Average selling price of cardiometabolic monitoring products, by region
  • 5.7 VALUE CHAIN ANALYSIS
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.9 IMPACT OF US TARIFFS-POC DIAGNOSTICS MARKET
    • 5.9.1 INTRODUCTION
    • 5.9.2 KEY TARIFF RATES
    • 5.9.3 PRICE IMPACT ANALYSIS
    • 5.9.4 IMPACT ON COUNTRIES/REGIONS
      • 5.9.4.1 North America
      • 5.9.4.2 Europe
      • 5.9.4.3 Asia Pacific

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 IMMUNOASSAYS
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 MOLECULAR DIAGNOSTICS
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 BIOCHEMICAL TECHNOLOGIES
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 LIST OF MAJOR PATENTS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GENERATIVE AI ON POC DIAGNOSTICS MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 TOP USE CASES AND MARKET POTENTIAL
    • 6.7.3 KEY COMPANIES IMPLEMENTING AI
    • 6.7.4 FUTURE OF AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 INDUSTRY STANDARDS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN POC DIAGNOSTICS
      • 7.2.1.1 Eco-friendly Initiatives
  • 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 REVENUE POTENTIAL
    • 8.5.2 COST DYNAMICS
    • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 9.1 INTRODUCTION
  • 9.2 BIOCHEMISTRY
    • 9.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
  • 9.3 IMMUNOASSAYS
    • 9.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
  • 9.4 MOLECULAR DIAGNOSTICS
    • 9.4.1 RT-PCR
      • 9.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market
    • 9.4.2 INAAT
      • 9.4.2.1 Emerging new pathogens to facilitate growth

10 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE

  • 10.1 INTRODUCTION
  • 10.2 BLOOD SAMPLES
    • 10.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
  • 10.3 NASAL & OROPHARYNGEAL SWABS
    • 10.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
  • 10.4 URINE SAMPLES
    • 10.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
  • 10.5 OTHER SAMPLES

11 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE

  • 11.1 INTRODUCTION
  • 11.2 PRESCRIPTION-BASED TESTING PRODUCTS
    • 11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
  • 11.3 OTC TESTING PRODUCTS
    • 11.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET

12 POINT OF CARE DIAGNOSTICS MARKET, BY END USER

  • 12.1 INTRODUCTION
  • 12.2 CLINICAL LABORATORIES
    • 12.2.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
  • 12.3 HOME CARE SETTINGS & SELF-TESTING
    • 12.3.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
  • 12.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
    • 12.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
  • 12.5 AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES
    • 12.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
  • 12.6 OTHER END USERS

13 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT

  • 13.1 INTRODUCTION
  • 13.2 GLUCOSE MONITORING PRODUCTS
    • 13.2.1 GLUCOSE MONITORING STRIPS
      • 13.2.1.1 Growing trend toward preventive healthcare to drive market
    • 13.2.2 GLUCOSE MONITORING METERS
      • 13.2.2.1 Growing technological advancements in glucose meters to propel market
    • 13.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES
      • 13.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth
  • 13.3 CARDIOMETABOLIC TESTING PRODUCTS
    • 13.3.1 CARDIAC MARKER TESTING PRODUCTS
      • 13.3.1.1 Growing government support for cardiovascular diseases to drive market
    • 13.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
      • 13.3.2.1 Need to optimize hospital workflow to favor growth
    • 13.3.3 HBA1C TESTING PRODUCTS
      • 13.3.3.1 Increasing recommendations by government healthcare authorities to boost market
  • 13.4 INFECTIOUS DISEASE TESTING PRODUCTS
    • 13.4.1 RESPIRATORY INFECTION TESTING PRODUCTS
      • 13.4.1.1 Influenza testing products
        • 13.4.1.1.1 Need for targeted treatments to expedite growth
      • 13.4.1.2 Tuberculosis testing products
        • 13.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth
      • 13.4.1.3 Other respiratory infection testing products
    • 13.4.2 HAI TESTING PRODUCTS
      • 13.4.2.1 Growing rate of surgical-site infections to boost market
    • 13.4.3 TROPICAL DISEASE TESTING PRODUCTS
      • 13.4.3.1 Rising incidence of malaria and dengue to support growth
    • 13.4.4 STD TESTING PRODUCTS
      • 13.4.4.1 HIV testing products
        • 13.4.4.1.1 Growing availability and awareness of testing products to boost market
      • 13.4.4.2 Hepatitis testing products
        • 13.4.4.2.1 Hepatitis B testing products
          • 13.4.4.2.1.1 Increasing prevalence of liver infections to favor growth
        • 13.4.4.2.2 Hepatitis C testing products
          • 13.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth
      • 13.4.4.3 Syphilis testing products
        • 13.4.4.3.1 Need for early and accessible diagnosis to expedite growth
      • 13.4.4.4 Human papillomavirus testing products
        • 13.4.4.4.1 Rising cases of cervical cancer to promote growth
      • 13.4.4.5 Chlamydia trachomatis testing products
        • 13.4.4.5.1 Growing adoption of advanced techniques to drive market
      • 13.4.4.6 Neisseria gonorrhea testing products
        • 13.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth
      • 13.4.4.7 HSV testing products
        • 13.4.4.7.1 Increasing incidence of herpes to support growth
    • 13.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
      • 13.4.5.1 Rising cases among hospitalized patients to boost demand
    • 13.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
  • 13.5 COAGULATION MONITORING PRODUCTS
    • 13.5.1 NEED FOR REGULAR MONITORING AND RISING DEMAND FOR HOME-USE KITS TO PROPEL MARKET
    • 13.5.2 PT/INR TESTING PRODUCTS
      • 13.5.2.1 Increasing number of atrial fibrillation cases to accelerate growth
    • 13.5.3 ACT/APTT TESTING PRODUCTS
      • 13.5.3.1 Rise in surgical procedures to speed up growth
  • 13.6 PREGNANCY & FERTILITY TESTING PRODUCTS
    • 13.6.1 PREGNANCY TESTING PRODUCTS
      • 13.6.1.1 Increasing awareness about family planning to stimulate growth
    • 13.6.2 FERTILITY TESTING PRODUCTS
      • 13.6.2.1 Growing infertility issues to fuel market
  • 13.7 TUMOR/CANCER MARKER TESTING PRODUCTS
    • 13.7.1 GROWING CANCER INCIDENCE AND GOVERNMENT SUPPORT FOR CANCER MANAGEMENT AND THERAPIES DRIVE MARKET
  • 13.8 URINALYSIS TESTING PRODUCTS
    • 13.8.1 INCREASING DEMAND FOR RAPID POC TESTING TECHNOLOGIES TO SUPPORT MARKET GROWTH
  • 13.9 CHOLESTEROL TESTING PRODUCTS
    • 13.9.1 GROWING GERIATRIC POPULATION AND RISING OBESITY LEVELS TO DRIVE MARKET
  • 13.10 HEMATOLOGY TESTING PRODUCTS
    • 13.10.1 RAPID DIAGNOSTICS AND MONITORING SUPPORT TO PROPEL END-USER ADOPTION
  • 13.11 DRUGS-OF-ABUSE TESTING PRODUCTS
    • 13.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
  • 13.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS
    • 13.12.1 GROWING PREVALENCE OF THYROID DISORDERS DRIVING DEMAND FOR TSH TESTING PRODUCTS
  • 13.13 FECAL OCCULT TESTING PRODUCTS
    • 13.13.1 GROWING INCIDENCE OF CANCER TO PROPEL THE MARKET
  • 13.14 OTHER PRODUCTS

14 POINT OF CARE DIAGNOSTICS MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 14.2.2 US
      • 14.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditure to aid growth
    • 14.2.3 CANADA
      • 14.2.3.1 Rising incidence of diabetes and infectious diseases to support growth
  • 14.3 EUROPE
    • 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 14.3.2 GERMANY
      • 14.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth
    • 14.3.3 FRANCE
      • 14.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market
    • 14.3.4 UK
      • 14.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth
    • 14.3.5 ITALY
      • 14.3.5.1 Growing burden of infectious and parasitic diseases to boost market
    • 14.3.6 SPAIN
      • 14.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth
    • 14.3.7 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 14.4.2 CHINA
      • 14.4.2.1 Increasing impact of diabetes on public health to amplify growth
    • 14.4.3 JAPAN
      • 14.4.3.1 Booming geriatric population to stimulate growth
    • 14.4.4 INDIA
      • 14.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth
    • 14.4.5 AUSTRALIA
      • 14.4.5.1 Growing research investments for next-gen POC devices to boost market
    • 14.4.6 SOUTH KOREA
      • 14.4.6.1 Growing focus on innovative diagnostic products to drive market
    • 14.4.7 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 14.5.2 BRAZIL
      • 14.5.2.1 Increasing public initiatives in healthcare to encourage growth
    • 14.5.3 MEXICO
      • 14.5.3.1 Need for frequent testing for disease management to expedite growth
    • 14.5.4 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
    • 14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

  • 15.1 INTRODUCTION
  • 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POC DIAGNOSTICS MARKET
  • 15.3 REVENUE ANALYSIS, 2023-2025
  • 15.4 MARKET SHARE ANALYSIS, 2025
  • 15.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 15.6 BRAND/PRODUCT COMPARISON
  • 15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 15.7.1 STARS
    • 15.7.2 EMERGING LEADERS
    • 15.7.3 PERVASIVE PLAYERS
    • 15.7.4 PARTICIPANTS
    • 15.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025
      • 15.7.5.1 Company footprint
      • 15.7.5.2 Region footprint
      • 15.7.5.3 Mode of purchase footprint
      • 15.7.5.4 Technology footprint
      • 15.7.5.5 Sample footprint
  • 15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 15.8.1 PROGRESSIVE COMPANIES
    • 15.8.2 RESPONSIVE COMPANIES
    • 15.8.3 DYNAMIC COMPANIES
    • 15.8.4 STARTING BLOCKS
    • 15.8.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
      • 15.8.5.1 Detailed list of key startups/SMEs
      • 15.8.5.2 Competitive benchmarking of startups/SMEs
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT LAUNCHES AND APPROVALS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 ABBOTT
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product launches and approvals
        • 16.1.1.3.2 Deals
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Right to win
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses and competitive threats
    • 16.1.2 F. HOFFMANN-LA ROCHE LTD
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Product launches and approvals
        • 16.1.2.3.2 Deals
        • 16.1.2.3.3 Expansions
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Right to win
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses and competitive threats
    • 16.1.3 SIEMENS HEALTHINEERS AG
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Product launches and approvals
        • 16.1.3.3.2 Deals
        • 16.1.3.3.3 Expansions
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Right to win
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses and competitive threats
    • 16.1.4 QUIDELORTHO CORPORATION
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Product launches and approvals
        • 16.1.4.3.2 Deals
        • 16.1.4.3.3 Expansions
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Right to win
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses and competitive threats
    • 16.1.5 DANAHER
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Product launches and approvals
        • 16.1.5.3.2 Deals
        • 16.1.5.3.3 Expansions
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Right to win
        • 16.1.5.4.2 Strategic choices
        • 16.1.5.4.3 Weaknesses and competitive threats
    • 16.1.6 WERFEN
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products offered
      • 16.1.6.3 Recent developments
        • 16.1.6.3.1 Product launches and approvals
        • 16.1.6.3.2 Deals
        • 16.1.6.3.3 Expansions
      • 16.1.6.4 MnM view
        • 16.1.6.4.1 Right to win
        • 16.1.6.4.2 Strategic choices
        • 16.1.6.4.3 Weaknesses and competitive threats
    • 16.1.7 BD
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Product launches and approvals
        • 16.1.7.3.2 Deals
        • 16.1.7.3.3 Expansions
    • 16.1.8 THERMO FISHER SCIENTIFIC INC.
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Deals
    • 16.1.9 BIOMERIEUX
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products offered
      • 16.1.9.3 Recent developments
        • 16.1.9.3.1 Product launches and approvals
        • 16.1.9.3.2 Deals
    • 16.1.10 EKF DIAGNOSTICS HOLDINGS PLC
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Product launches and approvals
        • 16.1.10.3.2 Expansions
        • 16.1.10.3.3 Other developments
    • 16.1.11 TRINITY BIOTECH
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Product launches and approvals
        • 16.1.11.3.2 Deals
    • 16.1.12 ORASURE TECHNOLOGIES, INC.
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products offered
      • 16.1.12.3 Recent developments
        • 16.1.12.3.1 Product launches and approvals
        • 16.1.12.3.2 Deals
    • 16.1.13 GRIFOLS S.A.
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products offered
      • 16.1.13.3 Recent developments
        • 16.1.13.3.1 Product launches and approvals
    • 16.1.14 QIAGEN
      • 16.1.14.1 Business overview
      • 16.1.14.2 Products offered
      • 16.1.14.3 Recent developments
        • 16.1.14.3.1 Product launches and approvals
        • 16.1.14.3.2 Deals
        • 16.1.14.3.3 Expansions
  • 16.2 OTHER PLAYERS
    • 16.2.1 NOVA BIOMEDICAL
      • 16.2.1.1 Business overview
      • 16.2.1.2 Products offered
      • 16.2.1.3 Recent developments
        • 16.2.1.3.1 Product launches and approvals
        • 16.2.1.3.2 Deals
    • 16.2.2 SEKISUI DIAGNOSTICS
      • 16.2.2.1 Business overview
      • 16.2.2.2 Products offered
      • 16.2.2.3 Recent developments
        • 16.2.2.3.1 Product launches and approvals
    • 16.2.3 SEKISUI DIAGNOSTICS
      • 16.2.3.1 Business overview
      • 16.2.3.2 Products offered
      • 16.2.3.3 Recent developments
        • 16.2.3.3.1 Product launches and approvals
    • 16.2.4 LIFESCAN IP HOLDINGS, LLC
    • 16.2.5 PTS DIAGNOSTICS
    • 16.2.6 EUROLYSER DIAGNOSTICA GMBH
    • 16.2.7 RESPONSE BIOMEDICAL
    • 16.2.8 ALFA SCIENTIFIC DESIGNS, INC.
    • 16.2.9 BTNX INC.
    • 16.2.10 ASCENSIA DIABETES CARE HOLDINGS AG
    • 16.2.11 FLUXERGY
    • 16.2.12 PRECISION BIOSENSOR, INC.
    • 16.2.13 ACON LABORATORIES, INC.
    • 16.2.14 MENARINI DIAGNOSTICS S.R.L
    • 16.2.15 MANKIND PHARMA

17 RESEARCH METHODOLOGY

  • 17.1 RESEARCH DATA
  • 17.2 RESEARCH APPROACH
    • 17.2.1 SECONDARY RESEARCH
      • 17.2.1.1 Key data from secondary sources
    • 17.2.2 PRIMARY DATA
      • 17.2.2.1 Primary sources
      • 17.2.2.2 Key data from primary sources
      • 17.2.2.3 Key industry insights
  • 17.3 MARKET SIZE ESTIMATION
    • 17.3.1 BOTTOM-UP APPROACH
      • 17.3.1.1 Approach 1: Company revenue estimation approach
      • 17.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 17.3.1.3 Growth forecast
    • 17.3.2 TOP-DOWN APPROACH
  • 17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 17.5 MARKET SHARE ANALYSIS
  • 17.6 RESEARCH ASSUMPTIONS
    • 17.6.1 PARAMETRIC ASSUMPTIONS
    • 17.6.2 GROWTH RATE ASSUMPTIONS
  • 17.7 RESEARCH LIMITATIONS
  • 17.8 RISK ASSESSMENT

18 APPENDIX

  • 18.1 DISCUSSION GUIDE
  • 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 18.3 CUSTOMIZATION OPTIONS
  • 18.4 RELATED REPORTS
  • 18.5 AUTHOR DETAILS
Show more
Product Code: MD 2702

List of Tables

  • TABLE 1 PROJECTED INCREASE OF CANCER PATIENTS, BY REGION, 2025 VS. 2035 VS. 2045
  • TABLE 2 GLOBAL DIABETES ESTIMATES (AGES 20-79) BY REGION, 2024 VS. 2030 VS. 2045 (IN THOUSANDS)
  • TABLE 3 PRODUCT WAIVERS, BY KEY PLAYER, 2021-2026
  • TABLE 4 POC DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2024-2031
  • TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 7 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 11 POC DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 12 AVERAGE SELLING PRICE OF POC TESTS, BY PRODUCT, 2023-2025
  • TABLE 13 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2023-2025
  • TABLE 14 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2023-2025
  • TABLE 15 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2023-2025
  • TABLE 16 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2023-2025
  • TABLE 17 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 18 LIST OF MAJOR PATENTS PERTAINING TO POC DIAGNOSTICS MARKET, 2023-2025
  • TABLE 19 KEY COMPANIES IMPLEMENTING AI IN POC DIAGNOSTICS MARKET
  • TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 GLOBAL STANDARDS IN POC DIAGNOSTICS MARKET
  • TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
  • TABLE 27 KEY BUYING CRITERIA, BY TECHNOLOGY
  • TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • TABLE 29 POC DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • TABLE 30 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 31 KEY BIOCHEMISTRY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 32 POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 33 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 34 EUROPE: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 36 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 37 KEY IMMUNOASSAY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 38 POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 39 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 40 EUROPE: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 42 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 43 POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 44 POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 46 EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 48 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 49 KEY RT-PCR-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 50 POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 51 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 52 EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 53 ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 54 LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 55 KEY INAAT-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 56 POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 57 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 58 EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 60 LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 61 POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 62 KEY BLOOD SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 63 POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 64 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 65 EUROPE: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 67 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 68 KEY NASAL AND OROPHARYNGEAL SWAB-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 69 POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 70 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 EUROPE: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 73 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 74 KEY URINE SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 75 POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 76 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 77 EUROPE: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 78 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 79 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 80 KEY OTHER SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 81 POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 82 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 83 EUROPE: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 85 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 86 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 87 KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 88 POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 89 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 90 EUROPE: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 92 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 94 POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 95 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 96 EUROPE: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 98 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 99 POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 100 POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 101 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 102 EUROPE: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 104 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 105 POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 106 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 107 EUROPE: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 110 POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 111 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 112 EUROPE: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 114 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, B Y COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 115 POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 116 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 117 EUROPE: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 119 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 120 POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 121 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 122 EUROPE: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 124 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 125 POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 126 POC GLUCOSE MONITORING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 127 POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 128 NORTH AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 129 EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 131 LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 132 KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE
  • TABLE 133 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 134 NORTH AMERICA: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 135 EUROPE: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 137 LATIN AMERICA: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 138 KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE
  • TABLE 139 GLUCOSE MONITORING METERS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 140 NORTH AMERICA: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 141 EUROPE: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 142 ASIA PACIFIC: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 143 LATIN AMERICA: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 144 KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE
  • TABLE 145 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 146 NORTH AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 147 EUROPE: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 148 ASIA PACIFIC: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 149 LATIN AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 150 KEY CARDIOMETABOLIC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 151 POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 152 POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 153 NORTH AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 154 EUROPE: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 156 LATIN AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 157 CARDIAC MARKER TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 158 NORTH AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 159 EUROPE: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 161 LATIN AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 162 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 163 NORTH AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 164 EUROPE: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY REGION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 166 LATIN AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 167 HBA1C TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 168 NORTH AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 169 EUROPE: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 170 ASIA PACIFIC: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 171 LATIN AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 172 POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 173 POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 174 NORTH AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 175 EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 177 LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 178 RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 179 RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 180 NORTH AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 181 EUROPE: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 183 LATIN AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 184 KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 185 INFLUENZA TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 186 NORTH AMERICA: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 187 EUROPE: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 189 LATIN AMERICA: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 190 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 191 TUBERCULOSIS TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 192 NORTH AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 193 EUROPE: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 194 ASIA PACIFIC: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 195 LATIN AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 196 OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 197 OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 198 NORTH AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 199 EUROPE: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 200 ASIA PACIFIC: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 201 LATIN AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 202 KEY HAI TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 203 HAI TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 204 NORTH AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 205 EUROPE: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 207 LATIN AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 208 KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 209 TROPICAL DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 210 NORTH AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 211 EUROPE: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 213 LATIN AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 214 STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 215 STD TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 216 NORTH AMERICA: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 217 EUROPE: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 219 LATIN AMERICA: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 220 KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 221 HIV TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 222 NORTH AMERICA: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 223 EUROPE: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 224 ASIA PACIFIC: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 225 LATIN AMERICA: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 226 HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 HEPATITIS TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 228 NORTH AMERICA: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 229 EUROPE: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 231 LATIN AMERICA: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 232 KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 233 HEPATITIS B TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 234 NORTH AMERICA: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 235 EUROPE: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 237 LATIN AMERICA: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 238 KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 239 HEPATITIS C TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 240 NORTH AMERICA: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 241 EUROPE: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 242 ASIA PACIFIC: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 243 LATIN AMERICA: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 244 KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 245 SYPHILIS TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 246 NORTH AMERICA: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 247 EUROPE: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 248 ASIA PACIFIC: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 249 LATIN AMERICA: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 250 KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 251 HPV TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 252 NORTH AMERICA: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 253 EUROPE: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 254 ASIA PACIFIC: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 255 LATIN AMERICA: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 256 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 257 CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 258 NORTH AMERICA: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 259 EUROPE: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 260 ASIA PACIFIC: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 261 LATIN AMERICA: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 262 NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 263 NORTH AMERICA: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 264 EUROPE: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 265 ASIA PACIFIC: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 266 LATIN AMERICA: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 267 KEY HSV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 268 HSV TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 269 NORTH AMERICA: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 270 EUROPE: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 271 ASIA PACIFIC: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 272 LATIN AMERICA: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 273 KEY CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 274 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 275 NORTH AMERICA: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 276 EUROPE: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 277 ASIA PACIFIC: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 278 LATIN AMERICA: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 279 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 280 OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 281 NORTH AMERICA: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 282 EUROPE: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 283 ASIA PACIFIC: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 284 LATIN AMERICA: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 285 POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 286 POC COAGULATION MONITORING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 287 NORTH AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 288 EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 289 ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 290 LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 291 PT/INR TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 292 NORTH AMERICA: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 293 EUROPE: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 295 LATIN AMERICA: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 296 ACT/APTT TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 297 NORTH AMERICA: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 298 EUROPE: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 299 ASIA PACIFIC: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 300 LATIN AMERICA: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 301 POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 302 POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 303 NORTH AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 304 EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 305 ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 306 LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 307 KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 308 PREGNANCY TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 309 NORTH AMERICA: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 310 EUROPE: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 311 ASIA PACIFIC: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 312 LATIN AMERICA: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 313 KEY FERTILITY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 314 FERTILITY TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 315 NORTH AMERICA: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 316 EUROPE: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 318 LATIN AMERICA: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 319 TYPES OF CANCER CASES WORLDWIDE, 2024VS. 2045
  • TABLE 320 KEY TUMOR/CANCER MARKER TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 321 POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 322 NORTH AMERICA: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 323 EUROPE: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 324 ASIA PACIFIC: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 325 LATIN AMERICA: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 326 KEY URINALYSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 327 POC URINALYSIS TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 328 NORTH AMERICA: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 329 EUROPE: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 330 ASIA PACIFIC: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 331 LATIN AMERICA: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 332 KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 333 POC CHOLESTEROL TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 334 NORTH AMERICA: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 335 EUROPE: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 336 ASIA PACIFIC: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 337 LATIN AMERICA: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 338 KEY HEMATOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 339 POC HEMATOLOGY TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 340 NORTH AMERICA: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 341 EUROPE: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 342 ASIA PACIFIC: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 343 LATIN AMERICA: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 344 KEY DRUGS-OF-ABUSE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 345 POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 346 NORTH AMERICA: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 347 EUROPE: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 348 ASIA PACIFIC: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 349 LATIN AMERICA: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 350 KEY THYROID-STIMULATING HORMONE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 351 POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 352 NORTH AMERICA: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 353 EUROPE: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 354 ASIA PACIFIC: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 355 LATIN AMERICA: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 356 KEY FECAL OCCULT BLOOD TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 357 POC FECAL OCCULT TESTING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 358 NORTH AMERICA: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 359 EUROPE: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 360 ASIA PACIFIC: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 361 LATIN AMERICA: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 362 OTHER KEY POC DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 363 OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 364 NORTH AMERICA: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 365 EUROPE: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 366 ASIA PACIFIC: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 367 LATIN AMERICA: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 368 POC DIAGNOSTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 369 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 370 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 371 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 372 NORTH AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 373 NORTH AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 374 NORTH AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 375 NORTH AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 376 NORTH AMERICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 377 NORTH AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 378 NORTH AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 379 NORTH AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 380 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 381 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 382 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 383 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 384 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 385 US: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 386 US: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 387 US: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 388 US: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 389 US: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 390 US: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 391 US: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 392 US: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 393 US: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 394 US: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 395 US: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 396 US: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 397 US: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 398 US: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 399 CANADA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 400 CANADA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 401 CANADA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 402 CANADA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 403 CANADA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 404 CANADA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 405 CANADA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 406 CANADA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 407 CANADA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 408 CANADA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 409 CANADA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 410 CANADA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 411 CANADA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 412 CANADA: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 413 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 414 EUROPE: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 415 EUROPE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 416 EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 417 EUROPE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 418 EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 419 EUROPE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 420 EUROPE: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 421 EUROPE: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 422 EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 423 EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 424 EUROPE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 425 EUROPE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 426 EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 427 EUROPE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 428 EUROPE: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 429 GERMANY: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 430 GERMANY: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 431 GERMANY: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 432 GERMANY: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 433 GERMANY: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 434 GERMANY: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 435 GERMANY: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 436 GERMANY: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 437 GERMANY: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 438 GERMANY: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 439 GERMANY: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 440 GERMANY: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 441 GERMANY: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 442 GERMANY: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 443 FRANCE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 444 FRANCE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 445 FRANCE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 446 FRANCE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 447 FRANCE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 448 FRANCE: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 449 FRANCE: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 450 FRANCE: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 451 FRANCE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 452 FRANCE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 453 FRANCE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 454 FRANCE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 455 FRANCE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 456 FRANCE: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 457 UK: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 458 UK: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 459 UK: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 460 UK: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 461 UK: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 462 UK: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 463 UK: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 464 UK: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 465 UK: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 466 UK: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 467 UK: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 468 UK: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 469 UK: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 470 UK: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 471 ITALY: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 472 ITALY: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 473 ITALY: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 474 ITALY: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 475 ITALY: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 476 ITALY: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 477 ITALY: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 478 ITALY: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 479 ITALY: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 480 ITALY: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 481 ITALY: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 482 ITALY: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 483 ITALY: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 484 ITALY: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 485 SPAIN: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 486 SPAIN: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 487 SPAIN: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 488 SPAIN: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 489 SPAIN: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 490 SPAIN: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 491 SPAIN: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 492 SPAIN: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 493 SPAIN: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 494 SPAIN: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 495 SPAIN: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 496 SPAIN: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 497 SPAIN: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 498 SPAIN: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 499 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 500 REST OF EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 501 REST OF EUROPE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 502 REST OF EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 503 REST OF EUROPE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 504 REST OF EUROPE: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 505 REST OF EUROPE: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 506 REST OF EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 507 REST OF EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 508 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 509 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 510 REST OF EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 511 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 512 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 513 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 514 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 515 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 516 ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 517 ASIA PACIFIC: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 518 ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 519 ASIA PACIFIC: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 520 ASIA PACIFIC: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 521 ASIA PACIFIC: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 522 ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 523 ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 524 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 525 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 526 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 527 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 528 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 529 CHINA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 530 CHINA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 531 CHINA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 532 CHINA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 533 CHINA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 534 CHINA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 535 CHINA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 536 CHINA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 537 CHINA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 538 CHINA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 539 CHINA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 540 CHINA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 541 CHINA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 542 CHINA: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 543 JAPAN: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 544 JAPAN: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 545 JAPAN: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 546 JAPAN: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 547 JAPAN: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 548 JAPAN: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 549 JAPAN: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 550 JAPAN: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 551 JAPAN: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 552 JAPAN: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 553 JAPAN: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 554 JAPAN: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 555 JAPAN: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 556 JAPAN: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 557 INDIA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 558 INDIA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 559 INDIA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 560 INDIA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 561 INDIA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 562 INDIA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 563 INDIA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 564 INDIA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 565 INDIA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 566 INDIA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 567 INDIA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 568 INDIA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 569 INDIA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 570 INDIA: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 571 AUSTRALIA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 572 AUSTRALIA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 573 AUSTRALIA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 574 AUSTRALIA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 575 AUSTRALIA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 576 AUSTRALIA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 577 AUSTRALIA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 578 AUSTRALIA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 579 AUSTRALIA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 580 AUSTRALIA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 581 AUSTRALIA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 582 AUSTRALIA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 583 AUSTRALIA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 584 AUSTRALIA: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 585 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 586 SOUTH KOREA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 587 SOUTH KOREA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 588 SOUTH KOREA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 589 SOUTH KOREA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 590 SOUTH KOREA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 591 SOUTH KOREA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 592 SOUTH KOREA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 593 SOUTH KOREA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 594 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 595 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 596 SOUTH KOREA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 597 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 598 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 599 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 600 REST OF ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 601 REST OF ASIA PACIFIC: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 602 REST OF ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 603 REST OF ASIA PACIFIC: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 604 REST OF ASIA PACIFIC: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 605 REST OF ASIA PACIFIC: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 606 REST OF ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 607 REST OF ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 608 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 609 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 610 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 611 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 612 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 613 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 614 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 615 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 616 LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 617 LATIN AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 618 LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 619 LATIN AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 620 LATIN AMERICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 621 LATIN AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 622 LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 623 LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 624 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 625 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 626 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 627 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 628 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 629 BRAZIL: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 630 BRAZIL: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 631 BRAZIL: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 632 BRAZIL: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 633 BRAZIL: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 634 BRAZIL: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 635 BRAZIL: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 636 BRAZIL: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 637 BRAZIL: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 638 BRAZIL: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 639 BRAZIL: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 640 BRAZIL: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 641 BRAZIL: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 642 BRAZIL: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 643 MEXICO: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 644 MEXICO: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 645 MEXICO: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 646 MEXICO: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 647 MEXICO: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 648 MEXICO: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 649 MEXICO: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 650 MEXICO: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 651 MEXICO: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 652 MEXICO: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 653 MEXICO: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 654 MEXICO: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 655 MEXICO: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 656 MEXICO: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 657 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 658 REST OF LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 659 REST OF LATIN AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 660 REST OF LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 661 REST OF LATIN AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 662 REST OF LATIN AMERICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 663 REST OF LATIN AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 664 REST OF LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 665 REST OF LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 666 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 667 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 668 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 669 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 670 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 671 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 672 MIDDLE EAST & AFRICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 673 MIDDLE EAST & AFRICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 674 MIDDLE EAST & AFRICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 675 MIDDLE EAST & AFRICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 676 MIDDLE EAST & AFRICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 677 MIDDLE EAST & AFRICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 678 MIDDLE EAST & AFRICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 679 MIDDLE EAST & AFRICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 680 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
  • TABLE 681 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 682 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 683 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024-2031 (USD MILLION)
  • TABLE 684 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 685 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES, JANUARY 2023-JUNE 2026
  • TABLE 686 POC DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 687 POC DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 688 POC DIAGNOSTICS MARKET: MODE OF PURCHASE FOOTPRINT
  • TABLE 689 POC DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 690 POC DIAGNOSTICS MARKET: SAMPLE FOOTPRINT
  • TABLE 691 POC DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 692 POC DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 693 POC DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 694 POC DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JUNE 2026
  • TABLE 695 ABBOTT: COMPANY OVERVIEW
  • TABLE 696 ABBOTT: PRODUCTS OFFERED
  • TABLE 697 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 698 ABBOTT: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 699 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 700 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 701 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 702 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 703 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023-JUNE 2026
  • TABLE 704 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 705 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 706 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 707 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 708 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023-JUNE 2026
  • TABLE 709 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 710 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 711 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 712 QUIDELORTHO CORPORATION: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 713 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2023-JUNE 2026
  • TABLE 714 DANAHER: COMPANY OVERVIEW
  • TABLE 715 DANAHER: PRODUCTS OFFERED
  • TABLE 716 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 717 DANAHER: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 718 DANAHER: EXPANSIONS, JANUARY 2023-JUNE 2026
  • TABLE 719 WERFEN: COMPANY OVERVIEW
  • TABLE 720 WERFEN: PRODUCTS OFFERED
  • TABLE 721 WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 722 WERFEN: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 723 WERFEN: EXPANSIONS, JANUARY 2023-JUNE 2026
  • TABLE 724 BD: COMPANY OVERVIEW
  • TABLE 725 BD: PRODUCTS OFFERED
  • TABLE 726 BD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 727 BD: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 728 BD: EXPANSIONS, JANUARY 2023-JUNE 2026
  • TABLE 729 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 730 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 731 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 732 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 733 BIOMERIEUX: PRODUCTS OFFERED
  • TABLE 734 BIOMERIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 735 BIOMERIEUX: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 736 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
  • TABLE 737 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED
  • TABLE 738 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 739 EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2023-JUNE 2026
  • TABLE 740 EKF DIAGNOSTICS HOLDINGS PLC: OTHER DEVELOPMENTS, JANUARY 2023-JUNE 2026
  • TABLE 741 TRINITY BIOTECH: COMPANY OVERVIEW
  • TABLE 742 TRINITY BIOTECH: PRODUCTS OFFERED
  • TABLE 743 TRINITY BIOTECH: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 744 TRINITY BIOTECH: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 745 ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 746 ORASURE TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 747 ORASURE TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 748 ORASURE TECHNOLOGIES, INC.: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 749 GRIFOLS S.A.: COMPANY OVERVIEW
  • TABLE 750 GRIFOLS S.A.: PRODUCTS OFFERED
  • TABLE 751 GRIFOLS S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 752 QIAGEN: COMPANY OVERVIEW
  • TABLE 753 QIAGEN: PRODUCTS OFFERED
  • TABLE 754 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 755 QIAGEN: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 756 QIAGEN: EXPANSIONS, JANUARY 2023-JUNE 2026
  • TABLE 757 NOVA BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 758 NOVA BIOMEDICAL: PRODUCTS OFFERED
  • TABLE 759 NOVA BIOMEDICAL: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 760 NOVA BIOMEDICAL: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 761 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 762 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED
  • TABLE 763 SEKISUI DIAGNOSTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 764 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 765 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED
  • TABLE 766 SEKISUI DIAGNOSTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 767 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW
  • TABLE 768 PTS DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 769 EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW
  • TABLE 770 RESPONSE BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 771 ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW
  • TABLE 772 BTNX INC.: COMPANY OVERVIEW
  • TABLE 773 ASCENSIA DIABETES CARE HOLDINGS AG: COMPANY OVERVIEW
  • TABLE 774 FLUXERGY: COMPANY OVERVIEW
  • TABLE 775 PRECISION BIOSENSOR, INC.: COMPANY OVERVIEW
  • TABLE 776 ACON LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 777 MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW
  • TABLE 778 MANKIND PHARMA: COMPANY OVERVIEW
  • TABLE 779 POC DIAGNOSTICS MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 POC DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • FIGURE 3 GLOBAL POC DIAGNOSTICS MARKET, 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN POC DIAGNOSTICS MARKET, 2023-2025
  • FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF POC DIAGNOSTICS MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN POC DIAGNOSTICS MARKET, 2026-2031
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 8 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 9 GLUCOSE MONITORING PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 10 PRESCRIPTION-BASED TESTING PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 11 BIOCHEMISTRY SEGMENT TO WITNESS LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 12 BLOOD SAMPLES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 13 HOME CARE SETTINGS & SELF-TESTING SEGMENT TO HOLD LARGEST MARKET SHARE
  • FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 15 POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16 REGIONAL INCIDENCE OF HIV, 2025
  • FIGURE 17 POC DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 18 POC DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 19 POC DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 20 INVESTMENT AND FUNDING SCENARIO, 2021-2024
  • FIGURE 21 POC DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 22 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES IN POC DIAGNOSTICS MARKET
  • FIGURE 23 PATENT ANALYSIS FOR POC DIAGNOSTICS
  • FIGURE 24 MARKET POTENTIAL OF AI IN POC DIAGNOSTICS MARKET
  • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY
  • FIGURE 26 KEY BUYING CRITERIA, BY TECHNOLOGY
  • FIGURE 27 NORTH AMERICA: POC DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 28 ASIA PACIFIC: POC DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN POC DIAGNOSTICS MARKET 2023-2025
  • FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
  • FIGURE 31 EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 33 POC DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 34 POC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 35 POC DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 36 POC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 37 ABBOTT: COMPANY SNAPSHOT (2025)
  • FIGURE 38 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
  • FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
  • FIGURE 40 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 41 DANAHER: COMPANY SNAPSHOT (2025)
  • FIGURE 42 WERFEN: COMPANY SNAPSHOT (2025)
  • FIGURE 43 BD: COMPANY SNAPSHOT (2025)
  • FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 45 BIOMERIEUX: COMPANY SNAPSHOT (2025)
  • FIGURE 46 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2025)
  • FIGURE 47 TRINITY BIOTECH: COMPANY SNAPSHOT (2025)
  • FIGURE 48 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2025)
  • FIGURE 50 QIAGEN: COMPANY SNAPSHOT (2025)
  • FIGURE 51 POC DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
  • FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 54 GLOBAL POC DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS
  • FIGURE 55 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 56 TOP-DOWN APPROACH
  • FIGURE 57 DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!